Valneva (NASDAQ:VALN) PT Lowered to $20.00 at HC Wainwright

Valneva (NASDAQ:VALN) had its target price lowered by HC Wainwright from $23.00 to $20.00 in a research note published on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s FY2024 earnings at $0.00 EPS.

Valneva Trading Down 1.1 %

Shares of NASDAQ:VALN opened at $5.63 on Friday. The business’s 50-day moving average is $6.77 and its 200 day moving average is $7.44. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.63 and a quick ratio of 2.15. Valneva has a 1 year low of $5.57 and a 1 year high of $14.49. The firm has a market capitalization of $456.82 million, a P/E ratio of -10.83 and a beta of 2.17.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02. The firm had revenue of $40.97 million for the quarter, compared to the consensus estimate of $46.83 million. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. On average, research analysts predict that Valneva will post 0.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. increased its stake in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 354,361 shares of the company’s stock after acquiring an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities & Exchange Commission. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.